Endeavor BioMedicines is a clinical-stage biotechnology company focused on developing innovative therapies for life-threatening diseases, particularly targeting fibrotic lung diseases and HER3-positive cancers. Their lead investigational candidate, ENV-101, is designed as an inhibitor of the Hedgehog (Hh) signaling pathway, which plays a crucial role in the abnormal wound-healing processes associated with idiopathic pulmonary fibrosis (IPF). Recent Phase 2a clinical trial results have shown that ENV-101 significantly improved lung function and reversed key measures of lung fibrosis in patients with IPF, suggesting its potential as a disease-modifying therapy that could change treatment expectations for this condition.

In addition to ENV-101, Endeavor is also developing ENV-501, a human epidermal growth factor receptor 3 (HER3)-targeted antibody-drug conjugate (ADC) aimed at treating HER3-positive solid tumors. This approach reflects the company's commitment to creating therapies that not only slow disease progression but also aim to reverse the underlying pathophysiology of these conditions. With a robust pipeline and promising clinical data, Endeavor BioMedicines is positioned to make significant contributions to the treatment landscape for patients facing these challenging diseases.

United States

Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company’s second investigational candidate, ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors. 

Endeavor BioMedicines

Company Details